Euroopa Liit -
eesti -
EMA (European Medicines Agency)
sohonos
ipsen pharma - palovarotene - myositis ossificans - muud lihas-skeleti süsteemi häirete ravimid - treatment of fibrodysplasia ossificans progressiva.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
diacomit
biocodex - stiripentool - müoklooniline epilepsia, alaealine - antiepileptics, - diacomit on näidustatud kasutamiseks koos klobasaami ja valproaadiga lisaravina tulekindlate generaliseerunud toonilis-klooniliste krampide patsientidel koos raske müoklooniline lapsekingades (müokloonilise epilepsia, dravet's sündroom) kelle krambihood ei ole piisavalt kontrollitud koos klobasaami ja valproaadiga.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
onglyza
astrazeneca ab - saxagliptin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
vanflyta
daiichi sankyo europe gmbh - quizartinib dihüdrokloriid - leukeemia, müeloidne, äge - antineoplastilised ained - ravi ägeda müeloidse leukeemia.